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Abstract We studied whether the L-adrenergic agonist, iso-
proterenol (ISO), regulates Na,K-ATPase in alveolar epithelial
cells (AEC) via a mitogen-activated protein kinase (MAPK)/
extracellular signaling related kinase (ERK) dependent path-
way. ISO increased ERK activity in AEC by 10 min via a L-
adrenergic receptor, protein kinase A (PKA)-dependent mechan-
ism. Activation of the MAPK pathway by ISO, resulted in
increased Na,K-ATPase L1 and K1 subunit protein abundance in
whole cell lysates, which resulted in functional Na,K-ATPases at
the basolateral membranes. ISO did not change the K1 or L1
mRNA steady state levels, but rapamycin, the inhibitor of the
mammalian target of rapamycin, also blocked the ISO-mediated
increase in Na,K-ATPase total protein abundance, suggesting a
posttranscriptional regulation. We conclude that ISO, regulates
the Na,K-ATPase in AEC via PKA, ERK and rapamycin-
sensitive mechanisms. ß 2000 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Pulmonary edema resolution depends on the ability of the
lung to clear £uid from the alveolar space. This process occurs
by active Na transport across the alveolar epithelium [1^4].
Vectorial Na movement in alveolar epithelial cells (AEC) is
regulated in part by Na,K-ATPases located at the cell baso-
lateral membranes (BLMs). [1,4^8]. The Na-K-ATPase is a
membrane bound protein comprised of a catalytic K subunit,
with a molecular mass of V112 kDa and a regulatory L sub-
unit, which has a molecular weight of V40 and 60 kDa [9^
12].
L-Adrenergic agonists have been shown to increase active
Na transport in isolated rat lungs by increasing Na,K-ATP-
ase function [13^15]. Isoproterenol (ISO) increased Na,K-
ATPase activity by recruiting Na,K-ATPase proteins from
intracellular pools to the AEC BLMs within 15 min [16].
However, the long-term mechanisms of the Na,K-ATPase reg-
ulation by L-adrenergic agonists have not been elucidated.
The mitogen-activated protein kinase/extracellular signaling
regulated kinase (MAPK/ERK) cascade is activated by a va-
riety of signals, including catecholamines [17^21]. This cas-
cade regulates the expression of speci¢c genes via transcrip-
tional and/or post-transcriptional mechanisms [18]. L-
Adrenergic agonists have been found to activate the MAPK/
ERK pathway [22^24], however, there are no studies relating
this pathway to Na,K-ATPase regulation. Thus, we set out to
study whether L-adrenergic agonists regulate Na,K-ATPase
via MAPK/ERKs by transcriptional or post-transcriptional
mechanisms. Our data suggest that L-adrenergic agonists reg-
ulate Na,K-ATPase K1 and L1 subunits via a cAMP, protein
kinase A (PKA), ERK-dependent pathway, by post-transcrip-
tional, rapamycin-sensitive mechanisms.
2. Materials and methods
2.1. Materials
Propanolol, H-89 and rapamycin, were purchased from Calbiochem
(La Jolla, CA, USA) and forskolin, ISO and ouabain were purchased
from Sigma (St. Louis, MO, USA). U0126, anti-P-ERK antibody and
anti-ERK antibody were purchased from Promega (Madison, WI,
USA) and [Q-32P]ATP and Percoll was from Amersham (Arlington
Heights, IL, USA). PD98059, Elk-1 fusion protein and antibodies
against P-(Thr202/Tyr204)-p44/42 and P-Elk-1, were purchased from
New England Biolabs (Beverly, MA, USA). Antibodies against Na,K-
ATPase L1-and K1-subunits were a generous gift from Dr. Martin-
Vasallo (University of La Laguna, Spain) and Dr. M. Caplan (Yale
University, CT, USA) respectively.
2.2. Cell isolation and culture
AEC were isolated from pathogen-free male Sprague^Dawley
rats (200^225 g), as previously described [6,16], according to the meth-
od of Dobbs et al. [25]. Brie£y, the lungs were digested with elastase
(3 U/ml; Worthington Biochemical, Freehold, NJ, USA), AEC were
puri¢ed by di¡erential adherence to IgG-pretreated dishes and cell
viability was assessed by trypan blue exclusion (s 95%). Cells were
resuspended in Dulbecco’s modi¢ed Eagle’s medium (Cellgro, VA,
AK, USA) containing 10% fetal bovine serum with 2 mM glutamine,
200 U/ml penicillin, 200 Wg/ml streptomycin and 0.5 Wg/ml amphoter-
icin B. Cells were seeded in 6 cm plates at 8 million per plate or 10 cm
plates at 18 million per plate (for Na,K-ATPase activities and BLM
isolation experiments) and incubated in a humidi¢ed atmosphere of
5% CO2, 95% air at 37‡C. The day of isolation is designated day 0.
All experimental conditions were tested in day 2 serum-starved cells.
Media was changed every 2 days.
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2.3. Cell lysate and BLM isolation
AEC were treated for the desired times, medium was aspirated, cells
were washed twice with cold phosphate-bu¡ered saline (PBS) and
total protein was isolated using 0.5 ml of lysis bu¡er (20 mM Tris,
pH 7.5; 150 mM NaCl; 1 mM EDTA; 1 mM EGTA; 1% Triton
X-100; 2.5 mM sodium pyrophosphate; 1 mM L-glycerolphosphate;
1 mM Na3VO4 ; 1 Wg/ml leupeptin, 1 mM PMSF, New England Bio-
labs) per 60 mm plate and centrifuged at 14 000Ug. BLMs were iso-
lated using a Percoll gradient as have been previously described
[13,16,26]. Brie£y, cells were scraped in PBS, centrifuged and resus-
pended in homogenization bu¡er (300 mM mannitol in 12 mM
HEPES, pH 7.6), homogenized and centrifuged twice to discard the
nuclear and mitochondrial pellet. The membrane pellet was resus-
pended in 1 ml of HB by gentle pipetting. To form a Percoll gradient,
0.19 g of undiluted Percoll (Pharmacia Biotech, Piscataway, NJ, USA)
was added to a 1 ml suspension. The suspension was gently mixed and
centrifuged at 48 000Ug for 30 min, and the ring of BLMs was col-
lected.
2.4. Western blot analysis
Total cell lysates or BLM proteins were measured by Bradford
assay (Bio-Rad, Hercules, CA, USA), resolved in 10% SDS^PAGE
and transferred to nitrocellulose membranes (Optitran, Scleicher and
Schuell, Keene, NH, USA). Incubation with speci¢c antibodies was
performed overnight at 4‡C. Blots were developed with an ECL-plus
detection kit (Amersham, Arlington Heights, IL, USA) used as rec-
ommended by the manufacturer and bands were analyzed by densito-
metric scan (Stratagene EagleSight, La Jolla, CA, USA).
2.5. ERK assay
AEC seeded in 6 cm plates, were serum-starved for 18^24 h and
treated with the di¡erent drugs for the desired time. Cell lysates were
obtained as described and the ERK activity was determined as de-
scribed in the p44/p42 MAPK assay kit manual by New England
Biolabs, which is based on the immunoprecipitation of the active
ERK with a phosphospeci¢c p44/p42 MAP kinase (Thr202/Tyr204)
monoclonal antibody in order to do an in vitro kinase assay using
Elk-1 as substrate. Samples (25 Wl) were fractionated in a 12.5% SDS^
PAGE and analyzed by immunoblotting using a phosphospeci¢c Elk-
1 antibody (New England Biolabs, Beverly, MA, USA) as a probe.
2.6. Determination of Na,K-ATPase activity in AEC cells
Na,K-ATPase activity was determined as described before [16].
Brie£y, after cells were incubated with the desired conditions for
7 days, they were placed on ice and washed twice with cold PBS,
and aliquots (V10 Wg of protein) were transferred to the Na,K-ATP-
ase assay medium, containing (in mM) 50 NaCl, 5 KCl, 10 MgCl2,
1 EGTA, 50 Tris^HCl, and 7 Na2ATP and [Q-32P]ATP (speci¢c ac-
tivity 3000 Ci/mmol) in tracer amounts (3.3 nCi/Wl). Cells were tran-
siently exposed to a thermic shock to render the membrane permeable
to ATP. The samples were incubated at 37‡C for 15 min and the
reaction was terminated by the addition of 700 Wl of a trichloroacetic
acid:charcoal (5:10 w/v) suspension and rapid cooling to 4‡C. After
the charcoal phase containing the unhydrolyzed nucleotide was sepa-
rated (12 000Ug for 5 min), the liberated 32P was counted in an
aliquot. The Na,K-ATPase activity was calculated as the di¡erence
between the samples assayed in the same medium but devoid of Na
and K and in the presence of 2.5 mM ouabain (ouabain-insensitive
ATPase activity).
2.7. RNA isolation and analysis by semiquantitative reverse
transcription-polymerase chain reaction (RT-PCR)
AEC total RNA was isolated using Rneasy total RNA (Qiagen,
Valencia, CA, USA) as described by the manufacturer. RNA was
quanti¢ed by measurement of absorbance at 260 nm. The RT reaction
was performed using the Superscript Preampli¢cation System (Gibco-
BRL, Grand Island, NY, USA) following the manufacturer’s instruc-
tions. The resultant cDNA were ampli¢ed by PCR using speci¢c
primers (L1 subunit: oligonucleotides that correspond to the positions
418^437 and 786^805, respectively, of the cDNA from the rat gene
(considering number 1 the ‘A’ of the ¢rst ATG of the gene); K1
subunit: oligonucleotides that correspond to the positions 37^54
and 1483^1500, respectively, of the cDNA from the rat gene) and
analyzed by agarose gel electrophoresis. The ampli¢ed bands were
quanti¢ed by densitometric scan (Stratagene EagleSight, La Jolla,
CA, USA) normalizing against the internal control gene G3PDH
(glyceraldehyde-3-phosphate dehydrogenase). The conditions of the
PCR were 94‡C, 1 min; 53‡C 1 min 30 s; 72‡C, 2 min; 25 cycles.
For the ampli¢cation of the control gene G3PDH, we used the rat
G3PDH Control Amplimer Set from Clontech (Palo Alto, CA, USA).
2.8. Statistical analysis
Data is reported as mean þ S.E.M. Statistical analysis was done by
one-way ANOVA and Tukey correction. Results were considered sig-
ni¢cant when P6 0.05.
Fig. 1. ISO activated ERK1/2 in AEC via a L-adrenergic receptor,
PKA-dependent pathway. A: Serum-starved AEC were incubated
with ISO at the indicated times and the ERK activity was deter-
mined as phosphorylation of the transcription factor Elk-1. B: Se-
rum-starved AEC were incubated with the adenyl cyclase activator
forskolin (FSK), 50 WM, for 15 min or with 1 WM ISO for 10 min
in the presence or absence or either the L-adrenergic receptor antag-
onist propanolol (PROP) (1 WM), the PKA inhibitor, H-89 (0.5 WM),
or the MEK inhibitors PD98059 (PD) (50 WM) or U0126 (U0)
(10 WM). Antagonists were added 15 min prior to ISO, except for
the MEK inhibitors, which were added 1 or 2 h prior to ISO. Rep-
resentative Western blots against phospho-Elk-1 and composite
graph that depicts the data as mean þ S.E.M. (n = 4). Control values
were assigned as 1. **P6 0.01 versus CT, *P6 0.05 versus CT.
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3. Results and discussion
L-Adrenergic agonists have been shown to regulate alveolar
£uid reabsorption in mammalian lungs [13^15,27]. The short-
term regulation of the Na,K-ATPase by ISO occurs by trans-
locating intracellular Na,K-ATPase proteins to the AEC
BLMs within 15 min of ISO stimulation [16]. Recently, it
has been reported that terbutaline increases the Na,K-ATPase
K1 subunit in AEC after 5 days of incubation [28] however,
the mechanisms involved in the Na,K-ATPase long-term reg-
ulation have not been elucidated. We sought to determine the
role of the MAPK/ERK pathway in the long-term regulation
of the Na,K-ATPase by L-adrenergic agonists.
As shown in Fig. 1A, ISO stimulated ERKs activity in AEC
by 10 min of incubation. This e¡ect was blocked by the
MEK1/2 inhibitors, PD98059 (50 WM) and U0126 (10 WM),
the L-adrenergic antagonist propanolol (1 WM) and by the
PKA inhibitor H-89 (1 WM) (Fig. 1B). Forskolin (50 WM),
an adenyl cyclase activator, also activated ERK1/2 in AEC
(Fig. 1B), con¢rming the involvement of PKA in ERK acti-
vation in AEC. These results suggest that ISO activates the
MAPK/ERK pathway via a cAMP, PKA-dependent pathway
in AEC, which is consistent with previous reports that show
PKA-dependent activation of MAPK/ERKs by L-adrenergic
agonists, either by the classical or by an alternative pathway
[22,29].
As shown in Fig. 2A, ISO increased Na,K-ATPase L1 sub-
unit protein abundance after 48 h of incubation and K1 sub-
unit after 120 h of incubation in whole cell homogenates,
these e¡ects were completely blocked by PD98059 (Fig. 2B)
and U0126 (Fig. 4), while cells incubated only with the MEK
inhibitor U0126 (Fig. 4) showed a non-signi¢cant decrease in
the Na,K-ATPase total protein amount. These results suggest
that ISO increases the Na,K-ATPase subunits total protein
abundance via a MAPK/ERK-dependent mechanism.
Because our cells needed to be incubated for 96 or 168 h in
some of our experiments, we studied the e¡ect of ISO and the
MEK inhibitors on the MAPK pathway at this time points.
For these experiments we used Western blots against the ac-
tive (phosphorylated) MAPK and against the total MAPK,
¢nding that neither ISO nor the MEK inhibitor U0126 had
any e¡ect on the total MAPK protein or the active MAPK
Fig. 2. ISO increased whole cell Na,K-ATPase K1 and L1 subunits protein abundance via a MAPK/ERK-dependent mechanism. Serum-starved
AEC were incubated with 1 WM ISO in the presence or absence of 50 WM PD for the indicated times. Medium and treatment were changed
every 2 days. Total protein was analyzed by Western blot against both subunits of the pump. A: Composite graphs showing the time course
for increase in total protein obtained for the di¡erent subunits expressed as mean þ S.E.M., with control values assigned as 1. *P6 0.05.
B: Composite graphs and representative blots showing that the increase in total Na,K-ATPase protein was ERK-dependent. ***P6 0.0001 as
compared to CT (n = 3 for 12 and 24 h, n = 4 for 48, 96, 120 and 168 h).
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(data not shown). These results suggest that the ISO-mediated
e¡ect on MAPK is transient.
Although the maximal increase in total protein was ob-
served at di¡erent time points for K1 and L1 Na,K-ATPase
subunits, both subunits were increased at the BLMs when
cells were incubated with ISO for either 96 or 168 h (Fig.
3A) resulting in a ISO-mediated, MAPK/ERK-dependent in-
crease in Na,K-ATPase activity (Fig. 3B), while the MEK
inhibitor by itself, did not a¡ect the basal activity of the
Na,K-ATPase. These ¢ndings further support that ISO in-
creases the total amount of functional Na,K-ATPases via a
MAPK/ERK pathway. There are previous studies reporting
that the Na pump subunits can be regulated di¡erentially in
time [11,30] or that overexpressing one subunit can lead to an
increase of both subunits at the cell BLMs [8,31]. We postu-
late that when the intracellular stores for one subunit are
depleted, the cell, triggered by ISO, synthesizes new protein,
replenishing these intracellular stores. Alternatively, the in-
creased L1 subunit could stabilize the K1 subunit, increasing
its half life, supporting a previously proposed role for the
Na,K-ATPase L1 subunit [9,32].
The increase in total protein abundance can occur by tran-
scriptional or post-transcriptional mechanisms. We did not
Fig. 3. ISO increased Na,K-ATPase protein amount at the BLMs
and Na,K-ATPase activity via MAPK. A: Serum-starved AEC were
incubated with ISO in the presence or absence of U0126 (U0)
(10 WM) for either 96 or 168 h and BLMs were analyzed by West-
ern blot against both subunits of the Na,K-ATPase. Results are ex-
pressed as mean þ S.D. *P6 0.05 as compared to CT (n = 3). Repre-
sentative blots are also shown. B: Serum-starved AEC were
incubated with ISO in the presence or absence of U0 for 7 days
and the Na,K-ATPase activity was assessed by [32P]ATP hydrolysis
as described. Results are expressed as mean þ S.E.M. *P6 0.05
(n = 3).
Fig. 4. Rapamycin blocked ISO-mediated regulation of the Na,K-
ATPase. Serum-starved AEC were incubated with ISO in the pres-
ence of rapamycin (RAPA) (50 ng/ml) or the MEK inhibitor U0126
(U0) (10 WM) for either 96 h, for the analysis of the L1 subunit (A)
or 168 h, for the analysis of the K1 subunit (B). Total protein was
analyzed by Western blotting. Results are expressed as mean þ S.D.
***P6 0.0001 as compared to CT (n = 4) and representative blots
are shown.
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¢nd signi¢cant changes in mRNA steady state levels after
incubation with ISO at the times studied (data not shown),
suggesting that the increase in Na,K-ATPase protein abun-
dance was post-transcriptionally regulated. This contrasts
with the recent report of Minakata et al. [28] where terbuta-
line, after 4 days of incubation, increased the K1 subunit
mRNA 1.5-fold as compared to controls. It is possible that
we failed to detect the increase in the mRNA levels, however,
more likely, the di¡erences can be explained by the di¡erent
experimental conditions used in the two studies. In our experi-
ments, cells were serum-starved before being incubated with
ISO because serum has di¡erent growth factors that have
been shown to stimulate MAPK, and serum by itself has
also been shown to upregulate Na,K-ATPase gene expression
[33].
Although MAPK/ERKs are best known for activating tran-
scription factors [34], this cascade has also been reported to
regulate post-transcriptional mechanisms related to the
translational machinery, speci¢cally, via the regulation of
the eukaryotic initiation factor 4E (eIF4E), the eIF4E-
binding protein (eIF4E-BP) and the p70s6K [35^38]. The
immunosuppressant rapamycin inhibits the mammalian target
of rapamycin (mTOR) [39] and two important steps in trans-
lational regulation of protein synthesis are known to be down-
stream of TOR, the eIF4E-BP and the p70s6K [35,36,40,41].
Thus, to examine whether the post-transcriptional regulation
could be mediated by rapamycin-sensitive mechanisms, se-
rum-starved AEC were incubated with ISO for 96 h (for the
L1 subunit analysis) or 168 h (for the K1 subunit analysis), in
the presence or absence of rapamycin (50 ng/ml). As shown in
Fig. 4, rapamycin inhibited the ISO-mediated increase in
Na,K-ATPase total cell protein abundance without a¡ecting
the basal Na,K-ATPase protein amount. These results suggest
that, the L-AR^PKA^MAPK pathway could be regulating
either the p70s6K, the eIF4E or both components of the trans-
lational machinery to increase the Na,K-ATPase protein
abundance. ISO, rapamycin or U0126 did not change actin
protein abundance in any of the groups (data not shown),
suggesting that the ISO-mediated e¡ect on the Na,K-ATPase
was speci¢c.
In summary, ISO post-transcriptionally regulates the Na,K-
ATPase via MAPK/ERK and rapamycin-sensitive pathways
in AEC. Further studies are warranted to elucidate the speci¢c
pathways and the post-transcriptional mechanisms that are
involved in this regulation.
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